Current aspects of the use of allergen-specific immunotherapy in patients with bronchial asthma: review of GINA 2024 updates and results of the EfficAPSI study

  • Authors: Kurbacheva O.M.1,2, Ilyina N.I.3, Namazova-Baranova L.S.4,5, Nenasheva N.M.6, Fedenko E.S.7, Kleiner D.8
  • Affiliations:
    1. National Research Center--Institute of Immunology Federal Medical-Biological Agency of Russia
    2. Russian University of Medicine
    3. National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia
    4. Pediatrics and Child Health Research Institute of Petrovsky National Research Centre of Surgery
    5. The Russian National Research Medical University named after N.I. Pirogov
    6. Russian Medical Academy of Continuous Professional Education
    7. National Research Center – Institute of Immunology Federal Medical-Biological Agency of Russia
    8. STALLERGENES Vostok LLC 7A, Bld.25, Staropetrovskiy proezd, entrance 2, floor 2 125130, Moscow, Russia
  • Section: Reviews
  • Submitted: 03.04.2025
  • Accepted: 28.04.2025
  • Published: 05.05.2025
  • URL: https://rusalljournal.ru/raj/article/view/17016
  • DOI: https://doi.org/10.36691/RJA17016
  • ID: 17016


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Bronchial asthma (AA) remains one of the most significant respiratory diseases in the world and in Russia. The number of patients with AA is steadily increasing, and disease control is not achieved in all patients, even with adequate pharmacotherapy.

The only currently available method for the treatment of respiratory allergy that can influence the natural course of the disease is allergen-specific immunotherapy (AIT). Scientific communities are focused on promoting disease-modifying solutions based on compelling clinical evidence in order to rethink approaches to the treatment of respiratory diseases and improve the quality of life of people with allergies. The updated GINA 2024 recommendations emphasize the importance of AIT, especially SLIT, in the management of AA, noting its ability to reduce the risk of onset and progression of the disease. The article examines the main provisions of new expert recommendations in the field of AIT and also presents the results of the EfficAPSI (Efficacy of Sublingual Immunotherapy in Asthma Prevention Study) study, one of the largest population-based studies examining the effect of SLIT on the course of asthma.

Full Text

Restricted Access

About the authors

Oksana M. Kurbacheva

National Research Center--Institute of Immunology Federal Medical-Biological Agency of Russia; Russian University of Medicine

Author for correspondence.
Email: kurbacheva@gmail.com
ORCID iD: 0000-0003-3250-0694

MD, Dr. Sci. (Med.), Professor

Россия, Moscow; Moscow

Natalya I. Ilyina

National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia

Email: instimmun@yandex.ru
ORCID iD: 0000-0002-3556-969X
SPIN-code: 6715-5650

MD, Dr. Sci. (Med.), Professor

Россия, 24, Kashirskoyw shosse, Moscow, 115522

Leyla S. Namazova-Baranova

Pediatrics and Child Health Research Institute of Petrovsky National Research Centre of Surgery; The Russian National Research Medical University named after N.I. Pirogov

Email: leyla.s.namazova@gmail.com
ORCID iD: 0000-0002-2209-7531

MD, Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences

Россия, Moscow; Moscow

Natalia M. Nenasheva

Russian Medical Academy of Continuous Professional Education

Email: 1444031@gmail.com
ORCID iD: 0000-0002-3162-2510
SPIN-code: 3363-6170

MD, Dr. Sci. (Med.), Professor

Россия, 2/1 Barrikadnaya street, 125993 Moscow

Elena S. Fedenko

National Research Center – Institute of Immunology Federal Medical-Biological Agency of Russia

Email: efedks@gmail.com
ORCID iD: 0000-0003-3358-5087
SPIN-code: 5012-7242

MD, Dr. Sci. (Medicine), Professor

Россия, Moscow

Dina Kleiner

STALLERGENES Vostok LLC
7A, Bld.25, Staropetrovskiy proezd,
entrance 2, floor 2
125130, Moscow, Russia

Email: kleiner.dina@gmail.com
ORCID iD: 0009-0005-2103-6234

MD, Dr. Sci. (Med.)

7A, Bld.25, Staropetrovskiy proezd, entrance 2, floor 2 125130, Moscow, Russia

References

  1. Global Initiative for Asthma. Global strategy for asthma management and prevention (2024 update). Fontana, WI, USA: GINA, 2024. Available at: https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf
  2. Bystritskaya E.V., Bilichenko T.N. The review of the bronchial asthma morbidity in the population of the Russian Federation. PULMONOLOGIYA. 2022;32(5):651-660. (In Russ.) https://doi.org/10.18093/0869-0189-2022-32-5-651-660
  3. Российские клинические рекомендации по лечению бронхиальной астмы, 2024.
  4. Vizel A.A., Vizel I.Yu., Belevsky A.S. A new approach to the treatment of bronchial asthma of any severity. Doctor.Ru. 2020; 19(5): 74–78. doi: 10.31550/1727-2378-2020-19-5-74-78 .
  5. Dharmage S.C., Perret J.L., Custovic A. Respirology. Epidemiology of asthma: latest global burden and trends. 2019;24(8):790–797. https://pubmed.ncbi.nlm.nih.gov/31162788/
  6. Borisova M.E. et al. “Bronchial asthma in the Russian Federation: current state and prospects for the development of medical care.” Pulmonology, 2021; 31(4): 4066. https://journal.pulmonology.ru/pulm/article/view/4066
  7. Sánchez-Borges M, Martin BL, Muraro AM, et al. The importance of allergic disease in public health: an iCAALL statement. World Allergy Organ J. 2018;11(1):8. https://doi.org/10.1186/s40413-0180187-2 .
  8. Layhadi, Janice A. et al. Mechanisms and Predictive Biomarkers of Allergen Immunotherapy in the Clinic 2024 Jan; 12(1):59-66. https://doi: 10.1016/j.jaip.2023.11.027.
  9. Rebecca Fortescue, Kayleigh M Kew, Marco Shiu Tsun Leung. Sublingual immunotherapy for asthma. Cochrane Database Syst Rev.2020 Sep 14;9(9):CD011293. https://doi.org/10.1002/14651858.CD011293.pub3 .
  10. Pascal Demoly, Mathieu Molimard, Jean-François Bergmann et al. Impact of liquid sublingual immunotherapy on asthma onset and progression in patients with allergic rhinitis: a nationwide population-based study (EfficAPSI study)” // The Lancet Regional Health – Europe 41 (2024) 100915 https://doi: 10.1016/j.lanepe.2024.100915 .
  11. Blanco C, Bazire R, Argiz L, Hernández-Peña J. Sublingual allergen immunotherapy for respiratory allergy: a systematic review // Drugs in Context 2018; 7: 212552. doi: 10.1002/14651858.CD011293.pub3
  12. Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2004;114(4):851–857. https://doi.org/10.1016/j.jaci.2004.07.012 .
  13. Wang L, Yin J, Fadel R, et al. House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma. Allergy. 2014; 69:1181–1188. https://doi.org/10.1111/all.12188 .
  14. Schmitt J, Schwarz K, Stadler E, Wustenberg EG. Allergy immunotherapy for allergic rhinitis effectively prevents asthma: results from a large retrospective cohort study. J Allergy Clin Immunol. 2015;136(6):1511–1516. https://doi.org/10.1016/j.jaci.2015.07.038 .
  15. Woehlk C, Von Bulow A, Ghanizada M, et al. Allergen immune therapy effectively reduces the risk of exacerbations and lower respiratory tract infections in both seasonal and perennial allergic asthma: a nationwide epidemiological study. Eur Respir J. 2022;60(5):2200446. https://doi.org/10.1183/13993003.00446-2022 .
  16. Schmitt J, Wustenberg E, Kuster D, et al. The moderating role of allergy immunotherapy in asthma progression: results of a population-based cohort study. Allergy. 2020;75(3):596–602. https://doi.org/10.1111/all.14020 .
  17. Fritzsching B, Contoli M, Porsbjerg C, et al. Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma: results from the REACT study, a retrospective cohort study. Lancet Reg Health Eur. 2022; 13:100275. https://doi.org/10.1016/j.lanepe.2021.100275 .
  18. Wahn U, Bachert C, Heinrich J, Richter H, Zielen S. Real-world benefits of allergen immunotherapy for birch pollen-associated allergic rhinitis and asthma. Allergy. 2019;74(3):594604. https://doi.org/10.1111/all.13598 .
  19. Devillier P, Molimard M, Ansolabehere X, et al. Immunotherapy with grass pollen tablets reduces medication dispensing for allergic rhinitis and asthma: a retrospective database study in France. Allergy. 2019;74(7):1317–1326. https://doi.org/10.1111/all.13705 .
  20. Vogelberg C, Brüggenjürgen B, Richter H, Jutel M. Real-world adherence and evidence of subcutaneous and sublingual immunotherapy in grass and tree pollen-induced allergic rhinitis and asthma. Patient Prefer Adherence. 2020; 14:827. https://doi.org/10.2147/PPA.S242957
  21. Virchow JC, Backer V, Kuna P, et al. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial. JAMA. 2016;315(16):17151725. https://doi.org/10.1001/jama.2016.3964 .
  22. Valovirta E, Petersen TH, Piotrowska T, et al. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol. 2018;141(2):529–538 e513. doi: 10.1016/j.jaci.2017.06.014
  23. Löwhagen O., et al. "Real-life impact of asthma control on patients’ quality of life in Europe." European Respiratory Review 2015. https://err.ersjournals.com/content/24/135/378
  24. Pascal Demoly, Mathieu Molimard, Jean-François Bergmann et al. Impact of liquid sublingual immunotherapy on asthma onset and progression in patients with allergic rhinitis: a nationwide population-based study (EfficAPSI study)” The Lancet Regional Health – Europe 41 (2024) 100915 https://doi.org/10.1016/j.lanepe.2024.100915
  25. Zielen S, Devillier P, Heinrich J, Richter H, Wahn U. Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: a retrospective, real-world database analysis. Allergy. 2018;73(1):165–177. https://doi.org/10.1111/all.13213 .
  26. Thétis-Soulié M, Hosotte M, Grozelier I, Baillez C, Scurati S, Mercier V. The MaDo real-life study of dose adjustment of allergen immunotherapy liquid formulations in an indication of respiratory allergic disease: reasons, practices, and outcomes. Front Allergy. 2022; 3:971155. https://doi.org/10.3389/falgy.2022.971155

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © ABV-press,



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies